dc.contributor.author
Bachamanda Somesh, Dipthi
dc.contributor.author
Klose, Kristin
dc.contributor.author
Maring, Janita A.
dc.contributor.author
Kunkel, Désirée
dc.contributor.author
Jürchott, Karsten
dc.contributor.author
Protze, Stephanie I.
dc.contributor.author
Klein, Oliver
dc.contributor.author
Nebrich, Grit
dc.contributor.author
Becker, Matthias
dc.contributor.author
Krüger, Ulrike
dc.contributor.author
Nazari-Shafti, Timo Z.
dc.contributor.author
Falk, Volkmar
dc.contributor.author
Kurtz, Andreas
dc.contributor.author
Gossen, Manfred
dc.contributor.author
Stamm, Christof
dc.date.accessioned
2025-09-23T13:21:35Z
dc.date.available
2025-09-23T13:21:35Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/49500
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-49222
dc.description.abstract
Background
Direct cardiac reprogramming is currently being investigated for the generation of cells with a true cardiomyocyte (CM) phenotype. Based on the original approach of cardiac transcription factor-induced reprogramming of fibroblasts into CM-like cells, various modifications of that strategy have been developed. However, they uniformly suffer from poor reprogramming efficacy and a lack of translational tools for target cell expansion and purification. Therefore, our group has developed a unique approach to generate proliferative cells with a pre-CM phenotype that can be expanded in vitro to yield substantial cell doses.
Methods
Cardiac fibroblasts were reprogrammed toward CM fate using lentiviral transduction of cardiac transcriptions factors (GATA4, MEF2C, TBX5, and MYOCD). The resulting cellular phenotype was analyzed by RNA sequencing and immunocytology. Live target cells were purified based on intracellular CM marker expression using molecular beacon technology and fluorescence-activated cell sorting. CM commitment was assessed using 5-azacytidine-based differentiation assays and the therapeutic effect was evaluated in a mouse model of acute myocardial infarction using echocardiography and histology. The cellular secretome was analyzed using mass spectrometry.
Results
We found that proliferative CM precursor-like cells were part of the phenotype spectrum arising during direct reprogramming of fibroblasts toward CMs. These induced CM precursors (iCMPs) expressed CPC- and CM-specific proteins and were selectable via hairpin-shaped oligonucleotide hybridization probes targeting Myh6/7-mRNA–expressing cells. After purification, iCMPs were capable of extensive expansion, with preserved phenotype when under ascorbic acid supplementation, and gave rise to CM-like cells with organized sarcomeres in differentiation assays. When transplanted into infarcted mouse hearts, iCMPs prevented CM loss, attenuated fibrotic scarring, and preserved ventricular function, which can in part be attributed to their substantial secretion of factors with documented beneficial effect on cardiac repair.
Conclusions
Fibroblast reprogramming combined with molecular beacon-based cell selection yields an iCMP-like cell population with cardioprotective potential. Further studies are needed to elucidate mechanism-of-action and translational potential.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
cell therapy
en
dc.subject
direct reprogramming
en
dc.subject
induced cardiomyocyte precursor
en
dc.subject
molecular beacon
en
dc.subject
myocardial infarction
en
dc.subject
transdifferentiation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Cardiomyocyte precursors generated by direct reprogramming and molecular beacon selection attenuate ventricular remodeling after experimental myocardial infarction
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
296
dcterms.bibliographicCitation.doi
10.1186/s13287-023-03519-w
dcterms.bibliographicCitation.journaltitle
Stem Cell Research & Therapy
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
14
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
37840130
dcterms.isPartOf.eissn
1757-6512